Health Catalyst Reports Third Quarter 2026 Results

Q: What were Health Catalyst's third-quarter 2026 revenue and earnings?

Health Catalyst reported revenue of $56.283 million and net income of $40.496 million, or $0.53 per diluted share. Revenue declined 26% year over year. Net income was largely driven by a $65.889 million gain on the sale of the Vitalware business.

Q: What is Health Catalyst's full-year 2026 financial outlook?

Health Catalyst reaffirmed expected 2026 revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million. Adjusted EBITDA is a non-GAAP earnings measure.

Q: How much cash and short-term investments did Health Catalyst hold at September 30, 2026?

Health Catalyst held $53.746 million in cash and cash equivalents and $25.245 million in short-term investments at September 30, 2026. At December 31, 2025, the respective balances were $50.814 million and $44.918 million.

Nine-month operating cash flow turned positive at $16.911 million, compared with $9.181 million used a year earlier.

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Health Catalyst (Nasdaq: HCAT) reported third-quarter 2026 revenue of $56.283 million, down year over year, while recording a net profit. Revenue fell 26%, and gross margin declined to 31% from 39%. Net income was $40.496 million, or $0.53 per diluted share, versus a $22.229 million loss a year earlier, largely driven by a $65.889 million gain on the Vitalware business sale.

The Vitalware divestiture closed July 31, 2026. The company attributed operating declines primarily to the sale and difficulties migrating from DOS to Ignite, partly offset by cost reductions. Adjusted EBITDA, a non-GAAP earnings measure, fell 94% to $779,000. Health Catalyst reaffirmed its 2026 outlook for revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million. At September 30, no debt remained on the balance sheet, versus current and long-term debt at December 31, 2025.

11 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

1 major · 15 points

Hollow bars mark forward-looking points. How the balance works

Positive

Major pointVitalware divestiture closed July 31, 2026; nine-month business-sale proceeds totaled $144.455 million. 1.2× market cap
Major pointDebt balances fell to zero at September 30, 2026, following $163.960 million in nine-month debt repayments. 1.4× market cap
Moderate pointNine-month operating cash flow improved to $16.911 million provided, versus $9.181 million used a year earlier.
Moderate pointThird-quarter operating expenses fell to $39.793 million from $55.325 million a year earlier.
Minor pointThird-quarter net income reached $40.496 million, versus a $22.229 million year-earlier loss, largely driven by the sale gain.

6 minor points

Minor pointThird-quarter diluted earnings reached $0.53 per share, versus a $0.32 loss a year earlier.
Minor point. Forward-looking: it has not happened yet and may not happen.Health Catalyst expects 2026 revenue of $246 million to $249 million under its reaffirmed outlook.
Minor point. Forward-looking: it has not happened yet and may not happen.Health Catalyst expects 2026 adjusted EBITDA of $18 million to $18.5 million under its reaffirmed outlook.
Minor pointThird-quarter stock-based compensation fell to $4.077 million from $7.039 million a year earlier.
Minor pointThird-quarter restructuring and related costs declined to $1.354 million from $4.772 million a year earlier.
Minor pointThird-quarter interest and other expense, net, declined to $540,000 from $4.679 million a year earlier.

Negative

Major pointNine-month goodwill impairment increased to $122.548 million from $28.769 million a year earlier. 1× market cap
Moderate pointThird-quarter revenue declined 26% year over year to $56.283 million.
Moderate pointThird-quarter gross profit declined 42% to $17.345 million; gross margin fell to 31% from 39%.
Moderate pointThird-quarter adjusted EBITDA declined 94% year over year to $779,000.
Moderate pointDOS-to-Ignite migration difficulties contributed to year-over-year operating declines, alongside the Vitalware divestiture.
Moderate pointDebt extinguishment generated a $9.494 million loss in the third quarter. 7.9% of market cap

9 minor points

Minor pointThird-quarter technology revenue fell to $40.686 million from $52.051 million a year earlier.
Minor pointThird-quarter professional services revenue fell to $15.597 million from $24.272 million a year earlier.
Minor pointThird-quarter adjusted gross profit fell 38% to $24.913 million; adjusted gross margin declined to 44% from 53%.
Minor pointThird-quarter acquisition-related costs, net, were $1.372 million, versus a $1.816 million credit a year earlier.
Minor pointNine-month revenue fell to $197.526 million from $236.457 million a year earlier.
Minor pointNine-month net loss widened to $111.067 million from $86.949 million a year earlier.
Minor pointNine-month loss per share widened to $1.50 from $1.25 a year earlier.
Minor pointNine-month operating loss widened to $92.820 million from $74.774 million a year earlier.
Minor pointCommon shares outstanding increased to 76,155,467 at September 30, 2026, from 72,027,332 at December 31, 2025.

News Explained

At September 30, 2026, Health Catalyst reported $53,746 thousand in cash and $25,245 thousand in short-term investments; nine-month operating cash flow was $16,911 thousand.

In its reported third-quarter results, Health Catalyst lists 76,155,467 common shares issued and outstanding at September 30, 2026, versus 72,027,332 at December 31, 2025; under the supplied dilution definition, the higher count reduces existing holders’ percentage ownership absent offsetting changes.

At September 30, 2026, the company reported $53,746 thousand in cash and equivalents and $25,245 thousand in short-term investments; operating cash flow for the nine months ended that date was $16,911 thousand.

Key Figures

Total revenue: $56,283 thousand; down 26% year over year Gross margin: 31% vs. 39% Net income: $40,496 thousand +4 more

Total revenue: $56,283 thousand; down 26% year over year; Third quarter 2026
Gross margin: 31% vs. 39%; Third quarter 2026 vs. third quarter 2025
Net income: $40,496 thousand; Third quarter 2026; the company attributed it largely to a $65.9 million gain on sale
Adjusted EBITDA: $779 thousand; down 94% year over year; Third quarter 2026
Gain on sale of business: $65.9 million; Vitalware Business sale; cited as a primary driver of third-quarter net income
Revenue guidance: $246 million to $249 million; Full-year 2026 outlook, reaffirmed
Adjusted EBITDA guidance: $18 million to $18.5 million; Full-year 2026 outlook, reaffirmed

Previous Earnings Reports

1 past event · Latest: Nov 10

Same Type 1 event

Nov 10
Q3 2025 earnings

24h Move

-5.6%

Revenue was $76.3M and adjusted EBITDA $12.0M; the company beat quarterly guidance and reaffirmed its outlook.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gaap, non-gaap financial measures, regulation fd, stock-based compensation

4 terms

gaap financial

"a GAAP measure"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

non-gaap financial measures financial

"Non-GAAP Financial Measures"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

regulation fd regulatory

"to comply with our disclosure obligations under Regulation FD"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

stock-based compensation financial

"including stock-based compensation, that are not within our control"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/05/2026 - 04:03 PM EST

SALT LAKE CITY, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended September 30, 2026.

“We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook,” said Simeon Kohl, President and Chief Executive Officer of Health Catalyst. “Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.”

Financial Highlights for the Three Months Ended September 30, 2026

Key Financial Metrics

	Three Months Ended September 30,						Year over Year Change
	2026⁽²⁾			2025			Year over Year Change
GAAP Financial Measures:	(in thousands, except percentages, unaudited)
Total revenue	$	56,283		$	76,323		(26	)%
Gross profit	$	17,345		$	29,979		(42	)%
Gross margin		31	%		39	%
Net income (loss)	$	40,496		$	(22,229	)	282	%
Non-GAAP Financial Measures:⁽¹⁾
Adjusted Gross Profit	$	24,913		$	40,133		(38	)%
Adjusted Gross Margin		44	%		53	%
Adjusted EBITDA	$	779		$	12,000		(94	)%

________________________

⁽¹⁾	^{These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.}

⁽²⁾	^{The net income generated during the three months ended September 30, 2026 was largely driven by a $65.9 million gain on sale of the Vitalware Business, while total revenue, gross profit, gross margin, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA decreased year-over-year primarily as a result of the divestiture of the Vitalware Business on July 31, 2026 and headwinds related to the migration from DOS to Ignite, partially offset by our cost reduction initiatives. See Management's Discussion and Analysis of Financial Condition and Results of Operations for more detail.}

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the full year of 2026, we expect:

Total revenue of $246 million to $249 million, and
Adjusted EBITDA of $18 million to $18.5 million.

We have not provided forward-looking guidance for net income (loss), the most directly comparable GAAP measure to Adjusted EBITDA, and therefore have not reconciled guidance for Adjusted EBITDA to net income (loss), because there are items that may impact net income (loss), including stock-based compensation, that are not within our control or cannot be reasonably forecasted.

Quarterly Conference Call Details

We will host a conference call to review the results today, Thursday, November 5, 2026, at 5:00 p.m. E.T. The conference call can be accessed by dialing (800) 343-5172 for U.S. participants, or (203) 518-9856 for international participants, and referencing conference ID “HCATQ326.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including our website (https://www.healthcatalyst.com/), our investor relations website (https://ir.healthcatalyst.com/), press releases, SEC filings, public conference calls, and social media, including our LinkedIn (https://www.linkedin.com/company/healthcatalyst) and our CEO’s social media accounts such as LinkedIn (https://www.linkedin.com/in/simeon-kohl-224a945/), in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, our growth and transformation strategies, our strategic priorities, and our financial outlook for the fourth quarter and full year 2026. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners, clients reducing or eliminating their spend with us, client churn or down-selling in connection with the migration to Ignite or otherwise; (v) fluctuations in our project-based, non-recurring revenue, (vi) macroeconomic challenges (including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto), natural disasters or any new public health crises, and regional or global conflicts (including in the Middle East); (vii) the divestiture of Vitalware may not achieve some or all of the expected benefits and may adversely affect our business; and (viii) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026, expected to be filed with the SEC on or about November 5, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Condensed Consolidated Balance Sheets
(in thousands, except share and per share data, unaudited)

	As of September 30,			As of December 31,
	2026			2025
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	53,746		$	50,814
Short-term investments		25,245			44,918
Accounts receivable, net⁽¹⁾		41,333			59,128
Prepaid expenses and other assets		12,643			14,447
Total current assets		132,967			169,307
Property and equipment, net		34,456			33,838
Intangible assets, net		50,077			77,678
Operating lease right-of-use assets		5,604			6,640
Goodwill		11,102			209,073
Other assets		3,213			6,107
Total assets	$	237,419		$	502,643
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	6,531		$	9,363
Accrued liabilities		25,847			18,697
Deferred revenue⁽¹⁾		42,109			56,107
Operating lease liabilities		3,660			3,779
Current portion of long-term debt		—			1,627
Total current liabilities		78,147			89,573
Long-term debt, net of current portion		—			151,624
Deferred revenue, net of current portion		1,026			410
Operating lease liabilities, net of current portion		12,093			14,208
Contingent consideration liabilities		—			250
Other liabilities		567			798
Total liabilities		91,833			256,863

Stockholders’ equity:
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of September 30, 2026 and December 31, 2025		—			—
Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 76,155,467 and 72,027,332 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively		1,620,284			1,608,840
Accumulated deficit		(1,475,713	)		(1,364,646	)
Accumulated other comprehensive income		1,015			1,586
Total stockholders’ equity		145,586			245,780
Total liabilities and stockholders’ equity	$	237,419		$	502,643

__________________

⁽¹⁾	^{Includes amounts attributable to related party transactions. See Note 18 in our condensed consolidated financial statements.}

Condensed Consolidated Statements of Operations
(in thousands, except per share data, unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Revenue:
Technology	$	40,686		$	52,051		$	138,949		$	156,409
Professional services		15,597			24,272			58,577			80,048
Total revenue		56,283			76,323			197,526			236,457
Cost of revenue, excluding depreciation and amortization:
Technology^(1)(2)(3)		16,166			17,203			51,637			53,120
Professional services^(1)(2)(3)		16,076			21,304			51,525			71,045
Total cost of revenue, excluding depreciation and amortization		32,242			38,507			103,162			124,165
Operating expenses:
Sales and marketing^(1)(2)(3)		8,563			14,361			29,508			42,305
Research and development^(1)(2)(3)		9,503			12,281			30,308			39,859
General and administrative^(1)(2)(3)⁽⁴⁾		11,999			16,069			37,887			38,515
Depreciation and amortization		9,728			12,614			32,822			37,618
Goodwill impairment		—			—			122,548			28,769
Total operating expenses		39,793			55,325			253,073			187,066
Gain on sale of business		65,889			—			65,889			—
Income (loss) from operations		50,137			(17,509	)		(92,820	)		(74,774	)
Loss on extinguishment of debt		(9,494	)		—			(9,494	)		—
Interest and other expense, net		(540	)		(4,679	)		(8,417	)		(11,838	)
Income (loss) before income taxes		40,103			(22,188	)		(110,731	)		(86,612	)
Income tax benefit (provision)		393			(41	)		(336	)		(337	)
Net income (loss) attributable to common stockholders	$	40,496		$	(22,229	)	$	(111,067	)	$	(86,949	)
Net income (loss) per share, basic	$	0.54		$	(0.32	)	$	(1.50	)	$	(1.25	)
Net income (loss) per share, diluted	$	0.53		$	(0.32	)	$	(1.50	)	$	(1.25	)
Weighted-average shares outstanding used in calculating net income (loss) per share, basic		75,386			70,377			73,990			69,525
Weighted-average shares outstanding used in calculating net income (loss) per share, diluted		75,932			70,377			73,990			69,525

_______________

⁽¹⁾	^{Includes stock-based compensation expense as follows:}

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Stock-Based Compensation Expense:	(in thousands)				(in thousands)
Cost of revenue, excluding depreciation and amortization:
Technology	$	145	$	205	$	335	$	719
Professional services		594		991		1,488		3,187
Sales and marketing		1,033		2,085		2,442		6,789
Research and development		817		972		1,773		3,421
General and administrative		1,488		2,786		4,518		8,789
Total	$	4,077	$	7,039	$	10,556	$	22,905

_______________

⁽²⁾	^{Includes acquisition-related costs, net, as follows:}

	Three Months Ended September 30,					Nine Months Ended September 30,
	2026		2025			2026		2025
Acquisition-related costs, net:	(in thousands)					(in thousands)
Cost of revenue, excluding depreciation and amortization:
Technology	$	—	$	11		$	1	$	118
Professional services		—		24			6		200
Sales and marketing		210		(25	)		213		416
Research and development		25		—			31		357
General and administrative		1,137		(1,826	)		5,516		(3,598	)
Total	$	1,372	$	(1,816	)	$	5,767	$	(2,507	)

_______________

⁽³⁾	^{Includes restructuring and other related costs as follows:}

	Three Months Ended September 30,					Nine Months Ended September 30,
	2026			2025		2026		2025
Restructuring and other related costs:	(in thousands)					(in thousands)
Cost of revenue, excluding depreciation and amortization:
Technology	$	(18	)	$	436	$	278	$	837
Professional services		151			650		717		1,792
Sales and marketing		207			1,947		1,567		2,299
Research and development		79			1,374		1,669		3,282
General and administrative		935			365		2,620		501
Total	$	1,354		$	4,772	$	6,851	$	8,711

_______________

⁽⁴⁾	^{Includes non-recurring lease-related charges as follows:}

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Non-recurring lease-related charges:	(in thousands)				(in thousands)
General and administrative	$	—	$	6,900	$	—	$	6,900
Total	$	—	$	6,900	$	—	$	6,900

Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)

	Nine Months Ended September 30,
	2026			2025
Cash flows from operating activities
Net loss	$	(111,067	)	$	(86,949	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense		10,556			22,905
Depreciation and amortization		32,822			37,618
Impairment of long-lived assets		—			6,900
Non-cash operating lease expense		1,726			2,231
Amortization of debt discount, issuance costs, and deferred financing costs		1,332			2,906
Investment discount and premium accretion		(697	)		(1,278	)
Provision for expected credit losses		1,048			1,410
Deferred tax provision		(230	)		(114	)
Change in fair value of contingent consideration liabilities		(250	)		(7,063	)
Loss on extinguishment of debt		9,494			—
Gain on sale of business		(65,889	)		—
Goodwill impairment		122,548			28,769
Other		110			(410	)
Change in operating assets and liabilities:
Accounts receivable, net		10,391			(2,709	)
Prepaid expenses and other assets		4,850			1,934
Accounts payable, accrued liabilities, and other liabilities		4,970			(15,729	)
Deferred revenue		(1,973	)		3,304
Operating lease liabilities		(2,830	)		(2,906	)
Net cash provided by (used in) operating activities		16,911			(9,181	)

Cash flows from investing activities
Proceeds from the sale and maturity of short-term investments		63,901			149,448
Purchase of short-term investments		(43,668	)		(57,224	)
Acquisition of businesses, net of cash acquired		—			(41,114	)
Capitalization of internal-use software		(13,584	)		(14,638	)
Purchases of property and equipment		(839	)		(695	)
Purchase of intangible assets		(909	)		(624	)
Proceeds from the sale of property and equipment		26			31
Proceeds from sale of business		144,455			—
Net cash provided by investing activities		149,382			35,184

Cash flows from financing activities
Proceeds from employee stock purchase plan		629			1,537
Repurchase of common stock		—			(5,000	)
Repayment of debt		(163,960	)		(231,885	)
Net cash used in financing activities		(163,331	)		(235,348	)
Effect of exchange rate changes on cash and cash equivalents		(30	)		5
Net increase (decrease) in cash and cash equivalents		2,932			(209,340	)

Cash and cash equivalents at beginning of period		50,814			249,645
Cash and cash equivalents at end of period	$	53,746		$	40,305

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Cost of Revenue, Adjusted Operating Expenses, Adjusted Net Income, and Adjusted Net Income per share, basic and diluted are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Gross profit is a GAAP financial measure that is calculated as revenue less cost of revenue, including depreciation and amortization of capitalized software development costs and acquired technology. We calculate gross margin as gross profit divided by our revenue. Adjusted Gross Profit is a non-GAAP financial measure that we define as gross profit, adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, and (iv) restructuring and other related costs, as applicable. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses.

We present both of these measures for our technology and professional services business. We believe these non-GAAP financial measures are useful in evaluating our operating performance compared to that of other companies in our industry, as these metrics generally eliminate the effects of certain items that may vary from company to company for reasons unrelated to overall profitability.

The following is a reconciliation of our Adjusted Gross Profit and Adjusted Gross Margin, in total and for technology and professional services, to gross profit and gross margin, the most directly comparable financial measures calculated in accordance with GAAP for the three months ended September 30, 2026 and 2025.

	Three Months Ended September 30, 2026
	(in thousands, except percentages)
	Technology			Professional Services			Total
Revenue	$	40,686		$	15,597		$	56,283
Cost of revenue, excluding depreciation and amortization		(16,166	)		(16,076	)		(32,242	)
Amortization of intangible assets, cost of revenue		(3,614	)		—			(3,614	)
Depreciation of property and equipment, cost of revenue		(3,082	)		—			(3,082	)
Gross profit		17,824			(479	)		17,345
Gross margin		44	%	(3) %				31	%
Add:
Amortization of intangible assets, cost of revenue		3,614			—			3,614
Depreciation of property and equipment, cost of revenue		3,082			—			3,082
Stock-based compensation		145			594			739
Restructuring and other related costs⁽¹⁾		(18	)		151			133
Adjusted Gross Profit	$	24,647		$	266		$	24,913
Adjusted Gross Margin		61	%		2	%		44	%

___________________

⁽¹⁾	^{Restructuring and other related costs include severance, restructuring program costs, and other team member costs from workforce reductions and restructuring. For additional details, refer to Note 20 in our condensed consolidated financial statements.}

	Three Months Ended September 30, 2025
	(in thousands, except percentages)
	Technology			Professional Services			Total
Revenue	$	52,051		$	24,272		$	76,323
Cost of revenue, excluding depreciation and amortization		(17,203	)		(21,304	)		(38,507	)
Amortization of intangible assets, cost of revenue		(4,554	)		—			(4,554	)
Depreciation of property and equipment, cost of revenue		(3,283	)		—			(3,283	)
Gross profit		27,011			2,968			29,979
Gross margin		52	%		12	%		39	%
Add:
Amortization of intangible assets, cost of revenue		4,554			—			4,554
Depreciation of property and equipment, cost of revenue		3,283			—			3,283
Stock-based compensation		205			991			1,196
Acquisition-related costs, net⁽¹⁾		11			24			35
Restructuring and other related costs⁽²⁾		436			650			1,086
Adjusted Gross Profit	$	35,500		$	4,633		$	40,133
Adjusted Gross Margin		68	%		19	%		53	%

___________________

⁽¹⁾	^{Acquisition-related costs, net include deferred retention expenses attributable to the Upfront, Intraprise, and KPI Ninja acquisitions. For additional details refer to notes 1 and 3 in our condensed consolidated financial statements.}
⁽²⁾	^{Restructuring and other related costs include severance and other team member costs from workforce reductions and restructuring. For additional details, refer to Note 20 in our condensed consolidated financial statements.}

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) adjusted for (i) interest and other expense, net, (ii) income tax provision (benefit), (iii) depreciation and amortization, (iv) stock-based compensation, (v) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities for potential earn-out payments, (vi) restructuring and other related costs, (vii) non-recurring lease-related charges, (viii) gain on sale of business, and (ix) loss on extinguishment of debt, as applicable. We view acquisition-related expenses when applicable, such as transaction costs (including third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations) and changes in the fair value of contingent consideration liabilities for potential earnout payments that are directly related to business combinations, as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period. We believe that excluding restructuring and other related costs, impairment of goodwill and intangible assets, non-recurring lease-related charges, loss on extinguishment of debt, and gain on sale of business, as applicable, allows for more meaningful comparisons between operating results from period to period as these are separate from the core activities that arise in the ordinary course of our business and are not part of our ongoing operations. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our Adjusted EBITDA to net income (loss), the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended September 30, 2026 and 2025.

	Three Months Ended September 30,
	2026			2025
	(in thousands)
Net income (loss)	$	40,496		$	(22,229	)
Add:
Interest and other expense, net		540			4,679
Income tax provision (benefit)		(393	)		41
Depreciation and amortization		9,728			12,614
Stock-based compensation		4,077			7,039
Acquisition-related costs, net⁽¹⁾		1,372			(1,816	)
Restructuring and other related costs⁽²⁾		1,354			4,772
Non-recurring lease-related charges⁽³⁾		—			6,900
Gain on sale of business⁽⁴⁾		(65,889	)		—
Loss on extinguishment of debt⁽⁵⁾		9,494			—
Adjusted EBITDA	$	779		$	12,000

__________________

⁽¹⁾	^{Acquisition-related costs, net include third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. During the three months ended September 30, 2025, the fair value of the contingent consideration related to the Upfront acquisition earnout decreased, resulting in a net reduction in expense. For additional details refer to Notes 1, 3, and 8 in our condensed consolidated financial statements.}
⁽²⁾	^{Restructuring and other related costs include severance, restructuring and retention program costs, and other team member costs from our restructuring plans, which included workforce reductions, as well as legal and advisory fees related to Project Nexus that are non-recurring and outside the ordinary course of our business. For additional details, refer to Notes 1 and 20 in our condensed consolidated financial statements.}
⁽³⁾	^{Non-recurring lease-related charges include the lease-related impairment charges related to our corporate office space designated for subleasing. For additional details, refer to Note 10 in our condensed consolidated financial statements.}
⁽⁴⁾	^{The gain on sale of business was related to the Vitalware Transaction that closed on July 31, 2026 with total consideration received of $146.3 million and $80.4 million of net assets disposed. For additional details, refer to Note 2 in our condensed consolidated financial statements.}
⁽⁵⁾	^{On July 31, 2026, we used the net cash proceeds received from the Vitalware Transaction, together with cash on hand, to voluntarily repay in full all outstanding obligations under the Credit Agreement and terminate the agreement. In connection with the repayment, we recognized a loss on extinguishment of debt due to the write-off of unamortized debt issuance costs, debt discount, and prepayment premiums. For additional details, refer to Note 11 in our condensed consolidated financial statements.}

Adjusted Cost of Revenue

Adjusted Cost of Revenue is a non-GAAP financial measure that we define as cost of revenue adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, and (iv) restructuring and other related costs, as applicable. We view these adjustments to allow for more meaningful comparisons between operating results from period-to-period as these are separate from the core activities that arise in the ordinary course of our business. Adjusted Cost of Revenue is also computable by subtracting Adjusted Gross Profit from revenue. We believe Adjusted Cost of Revenue provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of Adjusted Cost of Revenue to our cost of revenue, the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended September 30, 2026 and 2025.

	Three Months Ended September 30,
	2026			2025
	(in thousands)
Cost of revenue, excluding depreciation and amortization	$	32,242		$	38,507
Add:
Amortization of intangible assets, cost of revenue		3,614			4,554
Depreciation of property and equipment, cost of revenue		3,082			3,283
Cost of revenue		38,938			46,344
Less:
Amortization of intangible assets, cost of revenue		(3,614	)		(4,554	)
Depreciation of property and equipment, cost of revenue		(3,082	)		(3,283	)
Stock-based compensation		(739	)		(1,196	)
Acquisition-related costs, net⁽¹⁾		—			(35	)
Restructuring and other related costs⁽²⁾		(133	)		(1,086	)
Adjusted Cost of Revenue	$	31,370		$	36,190

__________________

⁽¹⁾

^{Acquisition-related costs, net include deferred retention expenses incurred as part of business combinations.}

⁽²⁾

^{Restructuring and other related costs include severance, restructuring and retention program costs, and other team member costs from our restructuring plans, which included workforce reductions, as well as legal and advisory fees related to Project Nexus that are non-recurring and outside the ordinary course of our business. For additional details, refer to Note 20 in our condensed consolidated financial statements.}

Adjusted Operating Expenses

Adjusted Operating Expenses is a non-GAAP financial measure that we define as total operating expenses adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities for potential earn-out payments, (iv) goodwill impairment, (v) restructuring and other related costs, and (vi) non-recurring lease related charges, as applicable. We view these adjustments to allow for more meaningful comparisons between operating results from period-to-period as these are separate from the core activities that arise in the ordinary course of our business. We believe Adjusted Operating Expenses provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of Adjusted Operating Expenses to our total operating expenses, the most directly comparable financial measure calculated in accordance with GAAP, as well as a calculation of total operating expenses and Adjusted Operating Expenses as a percentage of total revenue, for the three months ended September 30, 2026 and 2025.

	Three Months Ended September 30,
	2026			2025
	(in thousands)
Total operating expenses	$	39,793		$	55,325
Less:
Depreciation and amortization		(9,728	)		(12,614	)
Stock-based compensation		(3,338	)		(5,843	)
Acquisition-related costs, net⁽¹⁾		(1,372	)		1,851
Restructuring and other related costs⁽²⁾		(1,221	)		(3,686	)
Non-recurring lease-related charges⁽³⁾		—			(6,900	)
Adjusted Operating Expenses	$	24,134		$	28,133
Total operating expenses as a % of revenue		71	%		73	%
Adjusted Operating Expenses as a % of revenue		43	%		37	%

__________________

⁽¹⁾	^{Acquisition-related costs, net include third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. During the three months ended September 30, 2025, the fair value of the contingent consideration related to the Upfront acquisition earnout decreased, resulting in a net reduction in expense. For additional details refer to Notes 1, 3, and 8 in our condensed consolidated financial statements.}
⁽²⁾	^{Restructuring and other related costs include severance, restructuring and retention program costs, and other team member costs from our restructuring plans, which included workforce reductions, as well as legal and advisory fees related to Project Nexus that are non-recurring and outside the ordinary course of our business. For additional details, refer to Notes 1 and 20 in our condensed consolidated financial statements.}
⁽³⁾	^{Non-recurring lease-related charges include the lease-related impairment charges related to our corporate office space designated for subleasing. For additional details, refer to Note 10 in our condensed consolidated financial statements.}

Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share

Adjusted Net Income (Loss) is a non-GAAP financial measure that we define as net income (loss) adjusted for (i) stock-based compensation, (ii) amortization of acquired intangibles, (iii) restructuring and other related costs, (iv) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities, (v) goodwill impairment, (vi) non-cash interest expense related to debt facilities, (vii) non-recurring lease-related charges, (viii) gain on sale of business, and (ix) loss on extinguishment of debt, as applicable. We believe Adjusted Net Income (Loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of Adjusted Net Income (Loss) to our net income (loss), the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended September 30, 2026 and 2025.

	Three Months Ended September 30,
	2026			2025
Numerator:	(in thousands, except share and per share amounts)
Net income (loss)	$	40,496		$	(22,229	)
Add:
Stock-based compensation		4,077			7,039
Amortization of acquired intangibles		6,373			8,823
Restructuring and other related costs⁽¹⁾		1,354			4,772
Acquisition-related costs, net⁽²⁾		1,372			(1,816	)
Non-cash interest expense related to debt facilities		174			817
Non-recurring lease-related charges⁽³⁾		—			6,900
Gain on sale of business⁽⁴⁾		(65,889	)		—
Loss on extinguishment of debt⁽⁵⁾		9,494			—
Adjusted Net Income (Loss)	$	(2,549	)	$	4,306
Denominator:
Weighted-average shares outstanding used in calculating net income (loss) per share, basic and Adjusted Net Income (Loss) per share, basic		75,386,281			70,376,760
Weighted-average shares outstanding used in calculating net income (loss) per share, diluted		75,932,217			70,376,760
Non-GAAP weighted-average shares outstanding used in calculating Adjusted Net Income (Loss) per share, diluted		75,386,281			71,094,489

Net income (loss) per share, basic	$	0.54		$	(0.32	)
Net income (loss) per share, diluted	$	0.53		$	(0.32	)
Adjusted Net Income (Loss) per share, basic and diluted	$	(0.03	)	$	0.06

______________

⁽¹⁾	^{Restructuring and other related costs include severance, restructuring program costs, and other team member costs from workforce reductions and restructuring, as well as advisory fees related to Project Nexus that are non-recurring and outside the ordinary course of our business. For additional details, refer to Notes 1 and 20 in our condensed consolidated financial statements.}
⁽²⁾	^{Acquisition-related costs, net include third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. During the three months ended September 30, 2025, the fair value of the contingent consideration related to the Upfront acquisition earnout decreased, resulting in a net reduction in expense. For additional details refer to Notes 1, 3, and 8 in our condensed consolidated financial statements.}
⁽³⁾	^{Non-recurring lease-related charges include the lease-related impairment charges related to our corporate office space designated for subleasing. For additional details, refer to Note 10 in our condensed consolidated financial statements.}
⁽⁴⁾	^{The gain on sale of business was related to the Vitalware Transaction that closed on July 31, 2026 with total consideration received of $146.3 million and $80.4 million of net assets disposed. For additional details, refer to Note 2 in our condensed consolidated financial statements.}
⁽⁵⁾	^{On July 31, 2026, we used the net cash proceeds received from the Vitalware Transaction, together with cash on hand, to voluntarily repay in full all outstanding obligations under the Credit Agreement and terminate the agreement. In connection with the repayment, we recognized a loss on extinguishment of debt due to the write-off of unamortized debt issuance costs, debt discount, and prepayment premiums. For additional details, refer to Note 11 in our condensed consolidated financial statements.}

Health Catalyst Investor Relations Contact:
Stephanie St. Clair
Finance and Investor Relations, SVP
+1 (855)-309-6800
ir@healthcatalyst.com

Health Catalyst Media Contact:
Kathryn Larson
Director, Public Relations and Communications
media@healthcatalyst.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Health Catalyst's third-quarter 2026 revenue and earnings?

Health Catalyst reported revenue of $56.283 million and net income of $40.496 million, or $0.53 per diluted share. Revenue declined 26% year over year. Net income was largely driven by a $65.889 million gain on the sale of the Vitalware business.

What is Health Catalyst's full-year 2026 financial outlook?

Health Catalyst reaffirmed expected 2026 revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million. Adjusted EBITDA is a non-GAAP earnings measure.

How much cash and short-term investments did Health Catalyst hold at September 30, 2026?

Health Catalyst held $53.746 million in cash and cash equivalents and $25.245 million in short-term investments at September 30, 2026. At December 31, 2025, the respective balances were $50.814 million and $44.918 million.

Health Catalyst Reports Third Quarter 2026 Results